Important Safety Information

Read this before starting therapy

This page summarizes important safety information for prescription treatments that may be available through Eterna IQ. It does not replace conversations with your clinician or the full prescribing information for your specific medication.

Eterna IQ is a health technology company, not a prescriber. Prescribing decisions are made by independent, licensed healthcare providers.

Compounded medications

Prescription treatments offered through Eterna IQ may include compounded preparations from licensed partner pharmacies.

Compounded medications are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed.

Compounded GLP-1 therapies (semaglutide)

When prescribed for chronic weight management in appropriate patients, GLP-1 class therapies have important risks.

Thyroid C-cell tumors: In rodents, semaglutide caused thyroid C-cell tumors. It is unknown whether this occurs in humans. Do not use if you or a family member have had medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your clinician about a neck lump, trouble swallowing, or hoarseness.

Other serious risks may include pancreatitis, gallbladder disease, kidney problems from dehydration, hypoglycemia (especially with insulin or sulfonylureas), allergic reactions, and vision changes in patients with diabetic eye disease.

Do not use if pregnant or planning pregnancy without clinician guidance. Common side effects include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and fatigue.

Compounded GLP-1 therapies (tirzepatide)

When prescribed for chronic weight management in appropriate patients, tirzepatide has a similar risk profile to other GLP-1 class therapies.

Thyroid C-cell tumors: Do not use if you or a family member have had MTC or MEN 2. Seek care for neck mass, trouble swallowing, or persistent hoarseness.

Other serious risks may include pancreatitis, gallbladder disease, kidney problems, hypoglycemia, and allergic reactions.

Do not use if pregnant or planning pregnancy without clinician guidance. Common side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, and decreased appetite.

Sermorelin (compounded)

Sermorelin is a peptide that signals the pituitary gland. A licensed provider decides whether it is appropriate for you and how to monitor it.

Compounded sermorelin is not an FDA-approved drug product. Risks may include injection site reactions, flushing, headache, and changes in blood sugar.

Do not use sermorelin without clinician review of your medications, pregnancy status, and relevant medical history.

GHK-Cu (topical compounded copper peptide)

Eterna offers GHK-Cu in topical form only, after review by a licensed healthcare provider.

Compounded GHK-Cu is not an FDA-approved drug product. Application site irritation and allergic reactions may occur.

Do not use GHK-Cu without clinician review of your medications, pregnancy status, and relevant medical history.

NAD+ (compounded)

NAD+ is a coenzyme your cells use to make energy. A licensed provider decides whether compounded NAD+ is appropriate for you.

Compounded NAD+ is not an FDA-approved drug product. Risks may include injection site reactions, flushing, nausea, and interactions with other treatments.

Do not use NAD+ therapies without clinician review of your medications, pregnancy status, and relevant medical history.

Glutathione (compounded)

Glutathione is an antioxidant your body makes on its own. A licensed provider decides whether compounded glutathione is appropriate for you.

Compounded glutathione is not an FDA-approved drug product. Risks may include injection site reactions and, rarely, allergic reactions.

Do not use glutathione without clinician review of your medications, pregnancy status, and relevant medical history.

PT-141 (bremelanotide)

Compounded PT-141 (bremelanotide) is not FDA-approved. A licensed provider reviews your intake and decides whether it is appropriate for you.

Common side effects may include nausea, flushing, headache, and injection site reactions. It may cause a temporary rise in blood pressure; tell your clinician if you have high blood pressure or heart disease.

Do not use PT-141 without clinician review of your medications, pregnancy status, and relevant medical history.

Testosterone optimization / TRT

Testosterone therapy requires baseline and ongoing laboratory monitoring. Risks may include polycythemia (elevated red blood cell count), fertility effects, acne, fluid retention, sleep apnea worsening, and cardiovascular effects in some patients.

Testosterone can transfer to partners or children through skin contact. Follow clinician instructions for application site hygiene and covering treated skin.

TRT is not appropriate for everyone. Your clinician will review contraindications, including certain hormone-sensitive conditions, untreated severe sleep apnea, and uncontrolled heart failure.

Hormone pathway therapies

Hormone-related therapies (including clomiphene, enclomiphene, or DHEA when prescribed) require individualized evaluation and monitoring.

Risks vary by agent and may include mood changes, fertility effects, liver enzyme changes, and cardiovascular or metabolic effects. Follow all laboratory monitoring recommended by your clinician.

Report side effects

Contact your treating clinician promptly for concerning symptoms. For emergencies, call 911.

You may report side effects to FDA MedWatch at 1-800-FDA-1088 or www.fda.gov/medwatch.

Not all risks are listed here. Read all information provided with your medication and ask your clinician questions.

Contact

Clinical questions should be directed to your treating clinician. Platform questions: support@eternaiq.com.

Eterna IQ LLC